up to 80 h post mortem for quantitative analyses of immunologically relevant cellular molecules. acknowledgementsThe authors express their gratitude to Karin Westermann for assisting with the immunohistochemistry and Sheila Fryk for correction of the English. This study was supported by the 'Deutsche Forschungsgemeinschaft', project grant SFB587-B5.

No abstract

Background: The randomized, double-blind, phase III KEYNOTE-564 (NCT03142334) study met its primary endpoint of disease-free survival with adjuvant pembro vs placebo following surgery in pts with RCC. We present PRO findings for adjuvant pembro vs placebo in KEYNOTE-564.Methods: PRO were evaluated in all randomized pts with !1 dose study treatment and !1 completed assessment for the specific outcome. FKSI-DRS and EORTC QLQ-C30 were administered electronically at cycles 1, 5, 9, 13, and 17, treatment discontinuation, 30 days after last dose, and annually thereafter until recurrence or new therapy. Prespecified secondary endpoints included least square (LS) mean change in symptom scores as measured by FKSI-DRS and health-related quality of life as measured by the QLQ-C30 global health status/quality of life (GHS/QoL) and physical functioning (PF) scales from baseline to week 52. CIs were nominal and descriptive.

No abstract

No abstract